SCHEMBL7079739

SCHEMBL7079739

CN1Cc2ccccc2N(C(=O)NCc2nc3ccccc3n2CCc2ccccc2)[C@@H](CC(=O)O)C1=O

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
POLB P06746 5/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 2/20 0.42
RECQL P46063 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 2/20 0.41
HPGD P15428 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7545624 0.88 MEN1 (0.39) POLBL3MBTL1MEN1KMT2ALMNA
Trifluoroacetic Acid SCHEMBL7539242 0.86 TP53 (0.41) POLBL3MBTL1MEN1KMT2ALMNA
SCHEMBL7441028 0.72 ITGB3 (0.45) MEN1KMT2A
SCHEMBL7370429 0.72 PKM (0.36) MEN1KMT2AALDH1A1
SCHEMBL7399894 0.71 ITGB1 (0.41)
SCHEMBL8401242 0.70 ITGB3 (0.51)
SCHEMBL7338319 0.68 PARP1 (0.44) SMN1; SMN2ALDH1A1
SCHEMBL8525562 0.68 ITGB3 (0.39) POLBL3MBTL1MEN1KMT2AMAPT
SCHEMBL7910284 0.68 ITGB3 (0.39) POLBL3MBTL1MEN1KMT2AMAPT
SCHEMBL8468835 0.67 ITGB3 (0.70)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946180-A4 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORP (US) 2003-07-23 EP claimed
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 US claimed
EP-0946180-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1999-10-06 EP claimed
WO-1998015278-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1998-04-16 WO claimed
EP-0946180-A4 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORP (US) 2003-07-23 EP disclosed
US-20020032187-A1 Method for stimulating bone formation SMITHKLINE BEECHAM CORPORATION 2002-03-14 US disclosed
EP-0946180-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1999-10-06 EP disclosed
WO-1998015278-A1 METHOD FOR STIMULATING BONE FORMATION SMITHKLINE BEECHAM CORPORATION (US) 1998-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032187-A1 Method for stimulating bone formation BMP2, BMP4, SOST GAA 3216/4885POLB 3057/4885L3MBTL1 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.